Kymera Investor Day Presentation Deck

KYMERA KT-413 Registration Strategies Phase 2 open label study patients Phase 3 randomized KT-413 in combo vs SOC Waldenstrom's: 1st (AA) Approval: Phase 2 open label 2nd (Full) approval: Phase 3 KT-413 vs BTK 1st line PCNSL: Phase 2 open label study ©2021 KYMERA THERAPEUTICS, INC. First US Approval (Accelerated) 3rd Line R/R MYD88mut DLBCL Second US Approval (Full) 2nd Line R/R MYD88mut DLBCL + SOC Additional Label Expansions Waldenstrom's, PCNSL, 1st line + SOC DLBCL, Wild Type DLBCL, etc. KYMERA R&D DAY - December 16th, 2021 PAGE 56

View entire presentation